URINARY/KIDNEY DISORDERSClinical Outcomes Studies

PUK1 CHRONIC KIDNEY DISEASE (CKD) AMONG INPATIENTS WITH REDUCED KIDNEY FUNCTION (RKF) ON HOSPITAL ADMISSION
To evaluate the prevalence of chronic kidney disease (CKD) in hospitalized patients and determine the proportion of these patients with/without a diagnosis of CKD based on estimated glomerular filtration rates (eGFR). METHODS: A retrospective analysis of US hospital data in the Cerner Health Facts® database during January 2000 and March 2007 was conducted. Inclusion criteria were age 18 years, a SCr measurement 3-18 months before hospital admission and seven days before or three days after hospital admission. Patients who had dialysis, acute renal failure and/or mixed inpatient eGFR (some values <60 and others =60 mL/min/1.73m
2 ) were excluded. To minimize bias and misclassification due to hospitalization circumstances, 2 eGFR values <60 mL/min/1.73m 2 were used to designate patients with CKD. The first eGFR was determined from the closest SCr measurement within 3-18 months before hospitalization and the second eGFR was determined using a SCr seven days before or three days of hospital admission. The MDRD-4 equation was used to calculate eGFR. RESULTS: Of the 1,265,014 patients hospitalized over the seven years evaluation, 193,221 met the inclusion criteria. Approximately 21% of patients were subsequently excluded for dialysis, acute renal failure, and/or mixed eGFR (n = 40,937). Overall, 27% of patients (n = 41,495) had an eGFR < 60 mL/min/1.73m 2 at admission. Of these, 81% (n = 33,443) had an eGFR < 60 mL/ min/1.73m 2 prior to admission. Of this subset likely to have CKD based on chronically low eGFR, only 26% (n = 8,560) had a diagnosis of CKD at admission based on ICD-9-CM diagnosis. CONCLUSION: Our findings suggest that most patients with RKF upon hospital admission may have CKD. Of these, few seem to have supportive CKD diagnosis codes. Identification and diagnosis of this patient population during hospitalization may provide a unique opportunity to improve disease management during the inpatient stay or after discharge, and may result in earlier nephrology referrals if appropriate. University of Arizona College of Medicine, Tucson, AZ, USA OBJECTIVE: To determine the association of blood pressure (BP) control and trajectory of renal function over seven years in a cohort of hypertensive veterans; and to determine the association between different classes of antihypertensive medications and renal function quantified by glomerular filtration rate (GFR). METHODS: Data were obtained from Southern Arizona Veterans' Affairs Health Care System from January 1, 2000 through December 31, 2006. Inclusion criteria consisted of veterans Ն 21 and < 90 years of age with at least two systolic BP measurements, and two serum creatinine measurements at least 90 days apart who had an ICD-9 hypertension diagnosis. Veterans were divided into time-varying controlled or uncontrolled hypertension groups based upon JNC-7 definitions. Factors examined included age, sex, race/ethnicity membership, and antihypertensive medication use. Medication categories included angiotensin converting enzyme inhibitor (ACE), beta-blocker (BB), or calcium channel blocker (CCB) monotherapy, or combinations of ACE, BB, and CCB. GFR was estimated using serum creatinine level, age, sex, and race/ethnicity. Analysis was performed using a generalized linear mixed model with patient as random effect. RESULTS: A total of 25,819 subjects met inclusion/exclusion criteria: 12,411 with controlled and 13,406 with uncontrolled BP. Males comprised 11,669 of controlled and 12,864 of uncontrolled groups. Mean age (SD) at index was 64.9(11.9) and 66.6(11.6) years in the controlled and uncontrolled groups respectively. Annual decline in GFR was 0.32 ml/-/1.73m2 after adjusting for covariates and medication use. There was a significant interaction between BP control and age (p < 0.001). ACE, BB, CCB use was associated with higher GFR (1.1, 95% CI 0.7-1.4; 0.5, 95% CI 0.1-0.8; and 0.8, 95% CI 0.2-1.3 ml/ minute/1.73m2, respectively). CONCLUSION: This analysis identified a significant decrease in GFR over time. Persons with controlled BP taking antihypertensive therapy had higher GFR than those taking no medication suggesting that antihypertensive medication use preserves kidney function.
PUK2 LONGITUDINAL DECLINE OF RENAL FUNCTION IN HYPERTENSIVE VETERANS
Smith
PUK3 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION THAT MAY REQUIRE DRUG DOSAGE ADJUSTMENT
Gupta V, Derby KG, Tabak YP, Goetz A, Johannes RS, Darin R Cardinal Health, Marlborough, MA, USA OBJECTIVE: Failure to dose adjust for renal insufficiency during hospitalization can be a common cause for medication errors and are an important function for clinicians. We examined the prevalence, mortality and length of stay (LOS) for cases that exhibited changes in renal function during hospitalization. METHODS: We retrospectively analyzed 1,011,055 non-dialysis admissions who had at least two serum creatinine values during hospital stay across 74 hospitals that provided electronic laboratory results from [2003] [2004] [2005] [2006] . We used a modified Cockcroft-Gault (140-age)/SCr (x 0.85 for females) to determine baseline and changing creatinine clearance (eCrCl, ml/min). Cases were stratified based on eCrCl as normal (Ն 81 ml/min), mild (50-80 ml/min), moderate (16-49 ml/min), and advanced (Յ15 ml/min). Worsening or improvement was defined as cases that moved one or more eCrCl strata to another during hospitalization. Unadjusted hospital mortality (95% CI) and median LOS were evaluated. RESULTS: On admission 29.6% had normal, 34.4% had mild, 34.1% had moderate, and 1.9% had advanced eCrCl. Of these cases the eCrCl remained the same in 79.2%, worsened in 11.6% and improved in 9.2%. Mortality and median LOS was highest for worsening eCrCl (7.9 [CI:7.8-8.1] and 6 days) followed by those remaining the same (2.8 [CI:2.8-2.9] and 4 days) and those with improving eCrCl (1.8 [CI:1.7-1.9] and 4 days). Cases with Ն 2 strata worsening in eCrCl (0.5% of cases) had higher mortality and LOS (25.9 [CI:24.7-27.1] and 10 days) than those with moderate (5.0 [CI:4.9-5.1] and 5 days, 28.8% of cases) or advanced .8] and 5 days, 1.5% of cases) eCrCl that remained the same. CONCLUSION: Both improvement and worsening renal function necessitating potential dosage adjustment are common during hospitalization. Mortality and LOS is higher for cases that had worsening renal function. Comprehensive renal dosing programs have the potential of improving medication safety and related outcomes.
URINARY/KIDNEY DISORDERS-Cost Studies
PUK4 COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN MEXICO
Idrovo J 1 , Rivas R 2 , Zapata L 2 1 Guia Mark, Mexico, DF, Mexico, 2 Guia Mark, México, DF, Mexico OBJECTIVE: The treatment of chronic kidney disease (CKD) with dialysis is associated with the appearance of hyperphosphatemia, which contributes to the presence of vascular calcifications, thus increasing the probability of the occurrence of cardiovascular events and death in these patients. The objective of this analysis was to evaluate the incremental costeffectiveness of the use of sevelamer to manage hyperphosphatemia secondary to CKD from an institutional perspective. METHODS: A Markov model was created in TreeAge to estimate the costs and benefits of the treatment with sevelamer or calcium tablets in patients with renal failure considering a temporary horizon of 60 months. The transition probabilities were taken from clinical trials identified through a systematic review of literature. The effectiveness measure considered was an increase in patient survival. Data related to the use of resources were obtained from a nominal group and cost information was obtained from price lists and rates published by health institutions. In addition a univariate sensitivity analysis was performed on the probability of death for sevelamer group. Costs were estimated using 2007 prices and are expressed in US dollars (exchange rate of 10.93 pesos per US dollar Research Centre on the Portuguese Economy-CISEP, Lisboa, Portugal OBJECTIVE: To determine the incremental cost-effectiveness ratio (ICER) of cinacalcet as an adjuvant therapy for SHPT from the perspective of the Portuguese NHS. METHODS: A probabilistic Markov model was used to compare best standard care (BSC) with BSC plus cinacalcet. The model was developed in cycles of six months until the death of all patients. Patients were distributed according to the risk of hospital admission due to cardiovascular events, major or minor fractures and parathyroidectomies. The absence of events and/or death was also considered. The probabilities of SHPT's complications were obtained from the literature. Portuguese official mortality rates were weighted by the presence of renal insufficiency and by the PTH levels. Due to lack of alternative, the resources used (only direct medical costs) were estimated by a Delphi panel of eight nephrologists and by a physical medicine and rehabilitation specialist. Unit costs were obtained from Portuguese official sources. Market shares of medicines prescribed in outpatient services were selected from the IMS. RESULTS: Cinacalcet increases 0.4 life years (LY) per patient with SHPT. The use of cinacalcet saves hospital admissions and follow-up costs of secondary events, but is associated with an ICER of €53,682 per LY gained. However, if dialysis costs are not considered, the ICER is €32,374 per LY gained and the probability of being cost-effective increases from 61% to 83% if acceptability for reimbursement is limited at €50.000 per LY gained. CONCLU-SION: Using a €50,000 WTP threshold, cinacalcet was found cost-effective if the increased cost of dialysis was excluded. The inclusion of this cost (induced by a longer life expectancy) leads to an ICER of €53,682 per LY gained. A clear paradox arises here as the alternative becomes less cost-effective by increasing dialysis patients' longevity.
